Advertisement

Topics

Ipsen Announces Dysport® (abobotulinumtoxinA) Co-Promotion Agreement with Saol Therapeutics to Expand Commercial Reach in the United States

08:00 EDT 30 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Saol sales team to promote Dysport® for select approved therapeutic indications in U.S. hospitals Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that ...

Other Sources for this Article

Ipsen Biopharmaceuticals, Inc.
Marisol Peron, 908-275-6330
Vice President, North American Internal & External Communications
marisol.peron@ipsen.com
or
W2O Group
Elliot Fox, 212-257-6724
efox@w2ogroup.com

NEXT ARTICLE

More From BioPortfolio on "Ipsen Announces Dysport® (abobotulinumtoxinA) Co-Promotion Agreement with Saol Therapeutics to Expand Commercial Reach in the United States"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...